Search This Blog

Monday, January 13, 2025

Mirum prelims, cash, outlook

  2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate

- 2025 expected global net product sales of $420 million to $435 million

- VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026

https://www.businesswire.com/news/home/20250113693031/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.